Liability Coverage

Business

Alliance Resource Partners Posts Strong Q4, Sees Coal Demand Surge Amid Grid Reliability Concerns

Alliance Resource Partners (ARLP) reported robust fourth-quarter earnings, driven by cost discipline and a resilient coal market. The company provided optimistic 2026 guidance, citing strengthening demand from data centers, industrial growth, and recent winter storms that underscored coal's critical role in grid reliability.

Feb 2, 2026

Business

Mizuho Bullish on Erasca, Initiates Coverage with $16 Target Amid RAS Inhibitor Progress

Erasca (ERAS) gains significant analyst momentum as Mizuho initiates coverage with an 'Outperform' rating and a $16 price target, citing confidence in its 2026 proof-of-concept milestones for RAS-targeted cancer therapies.

Feb 2, 2026

Business

TD Cowen Initiates Coverage on Constellation Energy with Buy Rating, Sees Upside to $440 on Calpine Synergies

TD Cowen has launched coverage of Constellation Energy (CEG) with an optimistic Buy rating and a $440 price target, highlighting strategic benefits from its recent Calpine acquisition and a favorable outlook for power market dynamics through 2026.

Jan 30, 2026

Business

UBS Initiates Coverage on Zai Lab with Buy Rating, Touts Global Ambitions Beyond China

Swiss banking giant UBS has initiated coverage on Zai Lab Limited (NASDAQ: ZLAB) with a bullish 'Buy' rating and a $35 price target, highlighting the biopharma firm's strategic pivot from a China-focused player to a burgeoning global innovation platform with a promising proprietary pipeline.

Jan 30, 2026

Business

Stifel Initiates Coverage on Sportradar with Buy Rating, Sees Opportunity in Sports Betting's 'Rational Duopoly'

Analysts at Stifel have initiated coverage on sports data giant Sportradar Group AG (NASDAQ: SRAD) with a Buy rating and a $28 price target, citing its dominant market position and favorable industry dynamics as online sports betting consolidates.

Jan 30, 2026

Business

UBS Bets Big on Biotech Turnaround, Initiates Arcellx Coverage with $100 Target

UBS has launched coverage of Arcellx with a Buy rating and a $100 price target, signaling growing Wall Street confidence in a biotech sector recovery and spotlighting the company's promising CAR-T therapy for multiple myeloma.

Jan 30, 2026

Business

Marsh McLennan Launches 'Secure Harbor' to Anchor Senior Living Sector Amid Insurance Storm

Marsh McLennan Agency unveils a group captive insurance solution designed specifically for senior living communities, aiming to provide stable liability coverage and risk management support in a challenging market.

Feb 2, 2026

Business

Medicare's Obesity Drug Coverage Set to Fuel Lilly's Weight-Loss Pill Launch, CEO Says

Eli Lilly's CEO sees Medicare's new policy covering obesity treatments as a pivotal moment, poised to unlock access for millions of beneficiaries to its incoming oral drug, orforglipron, and intensify the market battle with Novo Nordisk.

Feb 2, 2026

Business

Beyond the Drill Bit: How EQT Powers the AI Boom and Grid Reliability

As AI data centers drive an unprecedented surge in U.S. power demand, natural gas producer EQT is positioning itself as a critical pillar of energy security. Its proven operational resilience during extreme weather events underscores a strategic shift from a pure commodity play to an essential infrastructure partner.

Jan 31, 2026

Business

Oracle's TikTok Partnership and AI Expansion: A High-Stakes Balancing Act on Growth and Reliability

Oracle's deepening role as TikTok's U.S. data guardian and its aggressive push into regulated AI sectors present a dual narrative of strategic growth and heightened operational scrutiny, following a service outage linked to its infrastructure.

Jan 30, 2026

Business

TD Cowen Stands By Alphatec (ATEC) With Buy Rating, Sees $20 Target Amid Coverage Shift

Despite a lowered price target following an analyst transition, TD Cowen maintains a bullish stance on Alphatec Holdings, citing undervalued growth drivers including a new regenerative bone graft partnership and a robust long-term revenue outlook.

Jan 30, 2026

Business

Alliance Resource Partners Beats Profit Expectations Amid Coal Market Transition, Eyes Growth in Royalties

Alliance Resource Partners (ARLP) posted a significant jump in fourth-quarter profit, driven by cost controls and investment gains, even as coal revenue softened. The partnership issued 2026 guidance pointing to robust contract coverage and a growing oil & gas royalty segment, while navigating challenges at a key Appalachian mine.

Feb 2, 2026

Business

Workday's AI Ambitions Face Critical Test as 2026 Looms, Analysts Say

Goldman Sachs initiates coverage on Workday with a Neutral rating, citing a crowded core market and a slower-than-expected AI strategy rollout. The firm identifies 2026 as a pivotal year for the HR and finance software giant to prove its technological evolution.

Jan 30, 2026

Beyond Medicare: The $100K+ Annual Health Costs Retirees Often Overlook

While Medicare provides a crucial safety net at 65, significant gaps in coverage for dental, vision, and long-term care can lead to six-figure annual expenses. Proactive planning with HSAs, specialized insurance, and strategic budgeting is essential to protect retirement savings.

Feb 2, 2026

Business

Freedom Capital Bullish on Mama's Creations, Sees National Growth and Innovation Driving Stock to $16

Freedom Capital initiates coverage on Mama's Creations (MAMA) with a Buy rating and a $16 price target, citing the company's expanding national footprint, product innovation, and strong recent earnings as key growth catalysts in the fresh meal sector.

Feb 2, 2026

Business

Piper Sandler Trims Price Target for Black Diamond Therapeutics Amid Model Review, Despite Recent Clinical Wins

Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.

Feb 2, 2026

Business

Altimmune Secures Analyst Backing as Pemvidutide Advances Toward Phase 3 MASH Trial

Barclays initiates coverage with an Overweight rating and $20 price target on Altimmune, citing strong fundamentals and pipeline potential. The biotech firm prepares to channel recent offering proceeds toward its pivotal Phase 3 development for metabolic liver disease treatment pemvidutide.

Feb 2, 2026

Business

Barclays Bullish on 4D Molecular Therapeutics, Sees M&A and Pricing Trends as Key Catalysts

Barclays initiates coverage of 4D Molecular Therapeutics with an Overweight rating and a $33 price target, citing a favorable industry backdrop with potential M&A tailwinds and shifting focus away from drug pricing pressures. The gene therapy developer also outlined key clinical milestones expected through 2026.

Feb 2, 2026

Business

William Blair Touts Rambus as a Leading Force in the Booming DRAM Market

Investment firm William Blair has initiated coverage on Rambus Inc. with an 'Outperform' rating, highlighting the chip designer's dominant market share in interface circuits and its strategic positioning to capitalize on surging demand from AI data centers and server DRAM upgrades.

Feb 2, 2026

Business

Palantir's AI Software Growth Exceeds 25% Annually, Phillip Securities Sees Major Upside with $208 Target

Phillip Securities initiates coverage of Palantir Technologies with a Buy rating, citing its AI software segment's robust growth and significant market expansion potential. A new partnership with Innodata aims to enhance Palantir's rodeo analysis platforms through advanced data services.

Feb 2, 2026